

Special Issue

Personalized Diagnosis and Treatment of Urological Diseases

Message from the Guest Editors

History: With the advent of molecular diagnostics and novel drug delivery systems, personalized therapy has revolutionized the management of conditions such as prostate cancer, benign prostatic hyperplasia (BPH), and recurrent urinary tract infections. **Aim and Scope:** This Special Issue aims to explore cutting-edge advancements in the personalized diagnosis and treatment of urological diseases. The focus will be on integrating clinical, genomic, and imaging data to develop tailored therapies and on how drug delivery systems can be optimized for individualized care. **Cutting-edge Research:** We are particularly interested in research that bridges the gap between novel diagnostic tools, such as AI-based imaging or biomarkers, and therapeutic interventions, including gene therapy, targeted drug delivery, and the application of 3D printing in urology. **Papers of Interest:** We welcome original research and comprehensive reviews that address personalized diagnostic techniques, innovative drug delivery systems, and therapeutic approaches in urology. Contributions that demonstrate translational applications and patient-centered outcomes are highly encouraged.

Guest Editors

Dr. Alexandru Ciudin

Urology Department, Hospital Universitari de Mollet, 08100 Barcelona, Spain

Dr. Lluís Peri

Urology Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain

Deadline for manuscript submissions

closed (10 April 2026)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/218558

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).